Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain resolution · patients with sore throat
Corticosteroids leads to higher complete resolution of pain at 24 hours compared with placebo (high certainty).
2 findings from 1 review
Time to initial pain relief (minutes) · patients with sore throat
1 finding from 1 review
Mean time to resolution of pain · patients with sore throat
1 finding from 1 review
Absolute reduction in pain measured by VAS · patients with sore throat
1 finding from 1 review
Adverse events · patients with sore throat
Corticosteroids showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence · patients with sore throat
Corticosteroids showed no clear difference in recurrence/relapse rates compared with placebo (moderate certainty).
1 finding from 1 review
Days missed from work or school · patients with sore throat
1 finding from 1 review
28‐Day all‐cause mortalitya · children and adults with sepsis
Corticosteroids probably leads to lower 28‐Day all‐cause mortalitya compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Long‐term mortalityc · children and adults with sepsis
Corticosteroids showed no clear difference in long‐term mortalityc compared with placebo or usual care (low certainty).
1 finding from 1 review
Hospital mortality · children and adults with sepsis
Corticosteroids probably leads to lower hospital mortality compared with placebo or usual care (moderate certainty).
1 finding from 1 review
ICU length of stay (general intensive care patients) · children and adults with sepsis
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · children and adults with sepsis
1 finding from 1 review
Number of participants with adverse events ‐ superinfection (up to longest · children and adults with sepsis
Corticosteroids showed no clear difference in number of participants with adverse events ‐ superinfection (up to… compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Number of participants with adverse events ‐ muscle weakness (up to longest · children and adults with sepsis
Corticosteroids leads to higher number of participants with adverse events ‐ muscle weakness (up to… compared with placebo or usual care (high certainty).
1 finding from 1 review
Early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28; day 60; and in hospital · adults with acute respiratory distress syndrome
Corticosteroids showed no clear difference in early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28;… compared with control (low certainty).
1 finding from 1 review
Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome
It is very uncertain whether corticosteroids changes late all‐cause mortality ( > 3 months) Reported at: 180 days compared with control (very low certainty).
1 finding from 1 review
Duration of mechanical ventilation · adults with acute respiratory distress syndrome
1 finding from 1 review
Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome
1 finding from 1 review